IRCT20200513047423N4已完成未知
Bio equivalence study of Hydrochlorothiazide 50 mg tablets manufactured by Fatak Chemie Pars pharmaceutical company and comparing pharmacokinetics results with Hydrochlorothiazide tablets manufactured by Novartis in healthy volunteers
Fatak Chemie Pars0 个研究点目标入组 24 人开始时间: 待定最近更新:
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 24
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 years 至 50 years（—）
- 性别
- All
入选标准
- •Healthy liver
- •Healthy Kidney
- •Observing BMI
- •Age range between 18 and 50 years
- •Male and female
排除标准
- 未提供
研究者
相似试验
招募中
Unknown
In vivo Bioequivalence study of Hydrochlorothiazide tabletIRCT20220211053992N21Tabriz University of Medical Sciences24
尚未招募
Unknown
Comparative in vivo evaluation of 2 Hydrochlorothiazide 50 mg Tablet formulations.IRCT20180620040164N51Karen Pharma and Food Supplement Co.24
进行中（未招募）
不适用
Efficacy and Safety of Hydrochlorothiazide Used as Add-on Therapy in Moderately to Severely Hypertensive Patients not Adequately Controlled by Olmesartan Medoxomil 40 mg MonotherapyEssential hypertensionMedDRA version: 8.1Level: LLTClassification code 10015488Term: Essential hypertensionEUCTR2006-003876-37-CZDAIICHI SANKYO EUROPE GmbH2,220
进行中（未招募）
1 期
Efficacy and Safety of Hydrochlorothiazide Used as Add-on Therapy in Moderately to Severely Hypertensive Patients not Adequately Controlled by Olmesartan Medoxomil 40 mg MonotherapyEficacia y seguridad de Hidroclorotiazida, utilizada como terapia adicional, en pacientes con hipertensión moderada a severa no controlados adecuadamente con Olmesartan MEdoxomil 40 mg en monoterapiaEssential hypertensionHipertensión esencialMedDRA version: 8.1Level: LLTClassification code 10015488Term: Essential hypertensionEUCTR2006-003876-37-ESDAIICHI SANKYO EUROPE GmbH1,500
进行中（未招募）
不适用
Efficacy and Safety of Hydrochlorothiazide Used as Add-on Therapy in Moderately to Severely Hypertensive Patients not Adequately Controlled by Olmesartan Medoxomil 40 mg MonotherapyEssential hypertensionMedDRA version: 8.1Level: LLTClassification code 10015488Term: Essential hypertensionEUCTR2006-003876-37-DEDAIICHI SANKYO EUROPE GmbH1,500